Chemotherapy-induced enterocutaneous fistula after perineal hernia repair using a biological mesh: a case report

Abstract: This is the first reported case of an enterocutaneous fistula as a late complication to reconstruction of the pelvic floor with a Permacol™ mesh after a perineal hernia. A 70-year-old man had a reconstruction of the pelvic floor with a biological mesh because of a perineal hernia after laparoscopic abdominoperineal resection. Nine months after the perineal hernia operation, the patient had multiple metastases in both lungs and liver. The patient underwent chemotherapy, including bevacizumab, irinotecan, calcium folinate, and fluorouracil. Six weeks into chemotherapy, the patient developed signs of sepsis and complained of pain from the right buttock. Ultrasound examination revealed an abscess, which was drained, guided by ultrasound. A computed tomography scan showed a subcutaneous abscess cavity located in the right buttock with communication to the small bowel. Operative findings confirmed a perineal fistula from the distal ileum to perineum. A resection of the small bowel with primary anastomosis was performed. The postoperative course was complicated by fluid and electrolyte disturbances, but the patient was stabilized and finally discharged to a hospice for terminal care after 28 days of hospital stay. It seems that hernia repairs with biological meshes have lower erosion and infection rates compared with synthetic meshes, and so far, evidence suggests that biological grafts are safe and effective in the treatment of pelvic floor reconstruction. There have been no reports of enteric fistulas after pelvic reconstruction with biological meshes. However, the development of intestinal fistulas after chemotherapy with bevacizumab has been described in the literature. Our case report supports this association between bevacizumab and fistula formation among rectal cancer patients, as symptoms of a fistula started only 6 weeks into bevacizumab treatment but approximately 12 months after the perineal hernia operation, even after pelvic reconstruction using a biological mesh and without local recurrence.

Keywords: rectal cancer, abdominoperineal resection, enterocutaneous fistula, perineal hernia, biological mesh

Introduction
Postoperative perineal hernia occurs after conventional abdominoperineal resection (APR) and after the extralevator technique of APR (extralevator abdominoperineal excision; ELAPE) or pelvic exenteration. It has traditionally been reported to have a low incidence, ranging from 0.6% to 7%. Various techniques, including primary suture, muscular flaps, and synthetic or biological meshes, have been used to repair the defect in the pelvic floor. Biological meshes are currently used in perineal reconstruction after ELAPE, but the literature on biologics in pelvic floor surgery is limited to case series/reports, with limited follow-up and lack of randomized trials. Only a few complications have been reported to date, such as seroma and perineal pain. To our knowledge, we present the first case of an enterocutaneous fistula as a late complication...
to reconstruction of the pelvic floor with a Permacol™ mesh (Covidien, Dublin, Ireland) after perineal hernia.

**Case report**

A 70-year-old man with a T3V1N0M0 rectal tumor underwent laparoscopic APR followed by adjuvant chemotherapy with oxaliplatin, fluorouracil, and calcium folinate. At 1 year control, radiological work-up and colonoscopy showed no signs of recurrence or distant metastases. Thirteen months after the APR, the patient developed a perineal hernia and had a reconstruction of the pelvic floor with a biological mesh (Permacol™) via a transperineal approach. The postoperative course was uneventful, and the initial follow-up with a pelvic–abdominal computed tomography (CT) scan 4 months after the surgery showed no signs of locoregional recurrence or reherniation. Nine months after the perineal hernia operation, the patient experienced weight loss. A thoracic–abdominal CT scan was performed and showed multiple metastases to the liver and lungs. The patient was treated with chemotherapy: bevacizumab, irinotecan, calcium folinate, and fluorouracil. Twelve months after the perineal hernia operation, but only 6 weeks into chemotherapy, the patient developed signs of sepsis with a high temperature, tachycardia, and hypotension and complained of pain in the right buttock. Physical examination showed signs of infection at the area. Possible differential diagnoses could have been local recurrence of the rectal cancer, intraabdominal abscess, or pelvis sepsis. We could have chosen to examine the patient with a positron emission tomography scan or, for example, an ultrasound (US)-guided biopsy, but we chose an acute US examination. This revealed an abscess, and drainage was established by a US-guided procedure. The patient was moved to an intensive unit and started treatment with intravenous fluids and broad-spectrum antibiotics. The following CT scan with contrast given through the drain showed a subcutaneous abscess cavity located in the perineum, with communication to the small bowel (Figure 1). The patient underwent a laparotomy, and operative findings confirmed a perineal fistula from the distal ileum (Figure 2). A resection of the small bowel with primary anastomosis was performed. The postoperative course was complicated by severe fluid and electrolyte disturbances. The patient was in the intensive care unit for a total of 16 days before treatment with pressors, intravenous fluids, and parenteral nutrition stabilized the patient. The perineal wound was treated with vacuum-assisted closure for a total of 20 days. There were no complications in the closure treatment. According to the patient’s request, he was discharged to hospice for terminal care after 28 days of hospital stay.

**Discussion**

Synthetic meshes have been used in the repair of perineal hernias, but they have limitations in potentially contaminated or infected fields, with risk for fistula formation, chronic inflammation, stiffness, erosion, small bowel adhesions, and chronic mesh infections.† Biological meshes use the collagen network of human, porcine, or bovine tissues instead of nonliving synthetic materials.
of synthetic materials, and they have theoretical advantages compared with synthetic meshes, such as superior incorporation and less risk of infection.1,2 More recently, they have been used to close the perineum after ELAPE and in the treatment of perineal hernias.3 There is now considerable literature to support the use of biologic meshes.1–3 Hübnner et al reviewed the use of flap reconstruction against reconstruction with a biological mesh after ELAPE. Perineal wound complications occurred in 28% of the participants and 3.5% developed a perineal hernia after reconstruction with a biological mesh compared with 32% and 3.9% after flap reconstruction, respectively.2 In our case, we used Permacol™ (Tissue Science Laboratories/Covidien plc, Dublin, Ireland), which is a natural acellular biological collagen that is gradually absorbed and replaced by the patient’s own collagen. There have been no reports of enteric fistulas after pelvic reconstruction with biological meshes. Ahmed et al recently reviewed pelvic floor reconstruction with either a synthetic or a biological mesh. They found 4% mesh erosion with nonabsorbable synthetic mesh repair in sacrocolpopexy, compared with 0% with biological graft repair. These lower erosion rates are reproduced in the repair of transvaginal rectocele, where using Permacol™ had 0% erosion compared with 7% erosion with synthetic mesh. Ahmad et al3 also report lower infection rates using Permacol™ (0%) versus synthetic mesh (13%) in transperineal rectocele repair.3

Although we used Permacol™ for pelvic reconstruction in our patient, other factors may have played a role in the enteric fistula formation. For example, chemotherapy against metastatic disease, and especially bevacizumab, is suspected to cause enteric fistulas. The incidence of gastrointestinal perforations in colorectal cancer patients treated with bevacizumab has been reported, ranging from 0.9 to 2.0.4 The relative risk of gastrointestinal perforation in patients with metastatic colorectal cancer treated with bevacizumab has been reported to be between 3.68 and 5.04.5 The majority of the gastrointestinal perforations occurred within the first 6 months of treatment with bevacizumab. Ganapathi et al investigated the correlation between bevacizumab treatment and fistula formation after resection of advanced colorectal cancer.6 A total of nine patients (4.1%), who had undergone surgical excision for colorectal cancer and subsequently received bevacizumab, developed enteric fistulas. It was pointed out that the development of fistulas was probably secondary to bevacizumab therapy, rather than a surgical complication. The average time elapsed from the initial operation to the initiation of bevacizumab was 23.6 (range, 9–42) months. The average time before developing a complication after treatment with bevacizumab was 3.9 (range, 1–9) months. In our case, reported symptoms of the fistula started 6 weeks into bevacizumab treatment and approximately 12 months after the perineal hernia operation. Thus, it seems most likely that the complication was a result of the bevacizumab treatment, rather than a complication to the perineal hernia repair with a Permacol™ mesh. There is no evidence that a late fistula caused by erosion or chemotherapy alters oncological outcome.

In conclusion, it seems that hernia repairs with biological meshes have lower erosion and infection rates compared with synthetic meshes, and so far, evidence suggests that biological grafts are safe and effective in the treatment of pelvic floor reconstruction. However, our case report supports the literature about the association between bevacizumab and fistula formation among rectal cancer patients, even after pelvic reconstruction using a biological mesh and without local recurrence.

Disclosure
The authors report no conflicts of interest in this work.

References